



(51) International Patent Classification:
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/EP2018/057482

(22) International Filing Date:
23 March 2018 (23.03.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10 2017 106 305.6 23 March 2017 (23.03.2017) DE
62/475,329 23 March 2017 (23.03.2017) US

(71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH
[DE/DE]; Paul-Ehrlich-Strasse 15, 72076 Tuebingen (DE).

(72) Inventors: ALTEN, Leonie; Weissdornweg 14, App. 161,
72076 Tuebingen (DE). MAURER, Dominik; Fleinerweg
7, 72116 Moessingen (DE). BUNK, Sebastian; Gertrud-
Baeumer-Str. 19/1, 72074 Tuebingen (DE). WAGNER,
Claudia; Nuertinger Strasse 32, 72074 Tuebingen (DE).
FERBER, Mathias; 1 Rue de Paradis, 75010 Paris (FR).

(74) Agent: BOEHMERT & BOEHMERT; Jan B. KRAUSS,
Pettenkoferstrasse 22, 80336 München (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:
13 December 2018 (13.12.2018)

(54) Title: T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME AGAINST PRAME POSITIVE CANCERS

(57) Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

